DOI: 10.1515/mr-2023-0058
Nanotechnology-based delivery systems to overcome drug resistance in cancer
Harsh Patel1
Jiaxin Li2
Letao Bo1
Riddhi Mehta3
Charles R.Ashby1
Shanzhi Wang1
Wei Cai4
Zhe-Sheng Chen5
1.College of Pharmacy and Health Sciences,St.John's University,New York,NY,USA2.College of Pharmacy and Health Sciences,St.John's University,New York,NY,USA;School of Pharmaceutical Sciences,Hunan University of Medicine,Huaihua,Hunan Province,China3.St.John's College of Liberal Arts and Sciences,St.John's University,New York,NY,USA4.School of Pharmaceutical Sciences,Hunan University of Medicine,No.492 Jinxi South Road,Huaihua,41800,Hunan Province,China5.College of Pharmacy and Health Sciences,St.John's University,No.8000 Utopia Parkway,Queens,New York,NY 11439,USA
摘要：Cancer nanomedicine is defined as the application of nanotechnology and nanomaterials for the formulation of cancer therapeutics that can overcome the impediments and restrictions of traditional chemotherapeutics.Multidrug resistance(MDR)in cancer cells can be defined as a decrease or abrogation in the efficacy of anticancer drugs that have different molecular structures and mechanisms of action and is one of the primary causes of therapeutic failure.There have been successes in the development of cancer nanomedicine to overcome MDR;however,relatively few of these formulations have been approved by the United States Food and Drug Administration for the treatment of cancer.This is primarily due to the paucity of knowledge about nanotechnology and the fundamental biology of cancer cells.Here,we discuss the advances,types of nanomedicines,and the challenges regarding the translation of in vitro to in vivo results and their relevance to effective therapies.
机标关键词：systemscancerbaseddeliverydrugnanotechnologyovercomeresistance
论文发表日期：2024-02-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：26( 5-30 )
英文信息